RU2012153681A - Способы диагностики, контроля и профилактики воспаления и смягчения воспалительных состояний у псовых - Google Patents
Способы диагностики, контроля и профилактики воспаления и смягчения воспалительных состояний у псовых Download PDFInfo
- Publication number
- RU2012153681A RU2012153681A RU2012153681/15A RU2012153681A RU2012153681A RU 2012153681 A RU2012153681 A RU 2012153681A RU 2012153681/15 A RU2012153681/15 A RU 2012153681/15A RU 2012153681 A RU2012153681 A RU 2012153681A RU 2012153681 A RU2012153681 A RU 2012153681A
- Authority
- RU
- Russia
- Prior art keywords
- vitamin
- diet
- epa
- dha
- levels
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Feed For Specific Animals (AREA)
Abstract
1. Способ обнаружения воспалительного состояния у псовых, который включает измерение уровней одного или нескольких воспалительных биологических маркеров в крови, где увеличенная экспрессия в крови коррелирует со сниженным воспалением в тканях.2. Способ по п. 1, где биологический маркер, подлежащий измерению, выбирают из одного или нескольких из: IL-6, ADAMTS-4, IFNG, HAS2, BGN, SOX-9, ADAMTS-5, MMP3, ACP5, IL1A, TNC, HAS3, COMP, IGF-1, GHR, пептидазы Xaa-Pro, RANKL, SMAD7, PGE2, TLR9, PLOD1 и SCL2A9.3. Способ по п. 1, который дополнительно включает измерение уровней ANXA1 в крови, где сниженные уровни уровней ANXA1 коррелируют со сниженным воспалением в ткани.4. Способ по п. 1, где воспалительное состояние лечат или контролируют посредством введения диеты, содержащей повышенные уровни одного или нескольких из DHA, EPA, витамина C, витамина E и/или L-карнитина относительно стандартной диеты.5. Способ по п. 4, где диету вводят в течение периода по меньшей мере в две недели.6. Способ по п. 4, где диета содержит DHA+EPA в количестве 0,25-5% по сухой массе.7. Способ по п. 4, где диета содержит по сухой массе:DHA + EPA: 0,5-2,5%Витамин C: 75-1000 мг/кгВитамин E: 250-1000 мг/кгL-карнитин: 100-1000 мг/кг8. Способ по п. 4, где диета имеет приблизительно следующую пищевую композицию в расчете на сухую массу:белки: 20%жиры: 16%углеводы: 51%сырая клетчатка: 9%карнитин: 351 мг/кгвитамин С: 225 м.д.витамин Е: 585 м.д.DHA: 0,3%ЕРА: 0,5%.9. Способ по любому из пп.1-8, где состояние, подлежащее контролю или лечению, представляет собой остеоартрит.
Claims (9)
1. Способ обнаружения воспалительного состояния у псовых, который включает измерение уровней одного или нескольких воспалительных биологических маркеров в крови, где увеличенная экспрессия в крови коррелирует со сниженным воспалением в тканях.
2. Способ по п. 1, где биологический маркер, подлежащий измерению, выбирают из одного или нескольких из: IL-6, ADAMTS-4, IFNG, HAS2, BGN, SOX-9, ADAMTS-5, MMP3, ACP5, IL1A, TNC, HAS3, COMP, IGF-1, GHR, пептидазы Xaa-Pro, RANKL, SMAD7, PGE2, TLR9, PLOD1 и SCL2A9.
3. Способ по п. 1, который дополнительно включает измерение уровней ANXA1 в крови, где сниженные уровни уровней ANXA1 коррелируют со сниженным воспалением в ткани.
4. Способ по п. 1, где воспалительное состояние лечат или контролируют посредством введения диеты, содержащей повышенные уровни одного или нескольких из DHA, EPA, витамина C, витамина E и/или L-карнитина относительно стандартной диеты.
5. Способ по п. 4, где диету вводят в течение периода по меньшей мере в две недели.
6. Способ по п. 4, где диета содержит DHA+EPA в количестве 0,25-5% по сухой массе.
7. Способ по п. 4, где диета содержит по сухой массе:
DHA + EPA: 0,5-2,5%
Витамин C: 75-1000 мг/кг
Витамин E: 250-1000 мг/кг
L-карнитин: 100-1000 мг/кг
8. Способ по п. 4, где диета имеет приблизительно следующую пищевую композицию в расчете на сухую массу:
белки: 20%
жиры: 16%
углеводы: 51%
сырая клетчатка: 9%
карнитин: 351 мг/кг
витамин С: 225 м.д.
витамин Е: 585 м.д.
DHA: 0,3%
ЕРА: 0,5%.
9. Способ по любому из пп.1-8, где состояние, подлежащее контролю или лечению, представляет собой остеоартрит.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33408410P | 2010-05-12 | 2010-05-12 | |
| US61/334,084 | 2010-05-12 | ||
| PCT/US2011/035429 WO2011143048A2 (en) | 2010-05-12 | 2011-05-05 | Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012153681A true RU2012153681A (ru) | 2014-06-20 |
| RU2564089C2 RU2564089C2 (ru) | 2015-09-27 |
Family
ID=44260025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012153681/15A RU2564089C2 (ru) | 2010-05-12 | 2011-05-05 | Способы диагностики, контроля и профилактики воспаления и смягчения воспалительных состояний у псовых |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10564169B2 (ru) |
| EP (1) | EP2569639B1 (ru) |
| JP (2) | JP6099560B2 (ru) |
| CN (1) | CN102884434B (ru) |
| AU (1) | AU2011253230B2 (ru) |
| BR (1) | BR112012025841A2 (ru) |
| CA (1) | CA2795575C (ru) |
| DK (1) | DK2569639T3 (ru) |
| ES (1) | ES2534246T3 (ru) |
| RU (1) | RU2564089C2 (ru) |
| WO (1) | WO2011143048A2 (ru) |
| ZA (1) | ZA201208037B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014295A2 (pt) * | 2011-12-12 | 2017-06-13 | Isis Innovation | método para determinar um estado de artrite reumatoide, kit para a determinação o estado de artrite reumatoide erosiva de um indivíduo, usos de tenancina-c, e de uma determinação do nível de tenascina-c, e, métodos para tratar uma condição inflamatória, e uma artrite reumatoide |
| EP2790528B1 (en) * | 2011-12-13 | 2018-05-23 | Hill's Pet Nutrition, Inc. | Lactic acid for use in preventing dental conditions |
| CN107582576A (zh) * | 2017-10-11 | 2018-01-16 | 杭州鑫伟低碳技术研发有限公司 | 一种具有生物消炎功能的组合物及其制备方法 |
| MX2021005967A (es) | 2018-11-21 | 2021-10-13 | Tremeau Pharmaceuticals Inc | Formas purificadas de rofecoxib, métodos de fabricación y uso. |
| JP7241653B2 (ja) * | 2019-09-18 | 2023-03-17 | 株式会社ダイセル | 反射防止材 |
| US11742069B2 (en) | 2021-02-01 | 2023-08-29 | Kpn Innovations, Llc. | Systems and methods for generating a nociception nourishment program |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
| US8377904B2 (en) | 2004-02-09 | 2013-02-19 | Hill's Pet Nutrition, Inc. | Composition and method for use in cartilage affecting conditions |
| WO2005110124A1 (en) | 2004-04-15 | 2005-11-24 | Abbott Laboratories | Composition and methods for nutritional management of patients with hepatic disease |
| CA2571742C (en) * | 2004-07-01 | 2013-01-15 | Nestec S.A. | Canine osteoarthritis diet formulation |
| RU2433819C2 (ru) | 2004-11-09 | 2011-11-20 | Хилл'С Пет Ньютришн, Инк. | Применение антиоксидантов для модуляции генов |
| WO2006074089A2 (en) * | 2004-12-30 | 2006-07-13 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| CA2592827C (en) | 2004-12-30 | 2013-08-13 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| GB2426581A (en) | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
| WO2007002837A2 (en) | 2005-06-29 | 2007-01-04 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatement of inflammatory disease |
| EP1979743A2 (en) | 2005-12-28 | 2008-10-15 | Hill's Pet Nutrition Inc. | Method of diagnosing a body weight condition or predisposition in an animal |
| EP1978984B1 (en) | 2006-02-01 | 2015-06-10 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| US7709215B2 (en) * | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
| BRPI0721829A2 (pt) * | 2007-07-09 | 2013-03-05 | Hills Pet Nutrition Inc | composiÇço de raÇço altamente digerÍvel para animal de estimaÇço, mÉtodos para reduzir o volume de fezes produzido por um animal, e para reduzir a quantidade de compostos contendo enxofre em fezes e assim reduzir o odor de fezes produzidas por um animal, e, uso de proteÍnas de qualidade elevada e carboidratos altamente digerÍveis |
| US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
| EP2323638B1 (en) | 2008-07-18 | 2014-05-07 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
-
2011
- 2011-05-05 EP EP11720361.2A patent/EP2569639B1/en active Active
- 2011-05-05 WO PCT/US2011/035429 patent/WO2011143048A2/en active Application Filing
- 2011-05-05 CN CN201180023613.1A patent/CN102884434B/zh not_active Expired - Fee Related
- 2011-05-05 JP JP2013510177A patent/JP6099560B2/ja active Active
- 2011-05-05 CA CA2795575A patent/CA2795575C/en active Active
- 2011-05-05 AU AU2011253230A patent/AU2011253230B2/en active Active
- 2011-05-05 BR BR112012025841A patent/BR112012025841A2/pt not_active IP Right Cessation
- 2011-05-05 RU RU2012153681/15A patent/RU2564089C2/ru not_active IP Right Cessation
- 2011-05-05 ES ES11720361.2T patent/ES2534246T3/es active Active
- 2011-05-05 DK DK11720361T patent/DK2569639T3/en active
- 2011-05-05 US US13/642,576 patent/US10564169B2/en active Active
-
2012
- 2012-10-24 ZA ZA2012/08037A patent/ZA201208037B/en unknown
-
2014
- 2014-12-05 JP JP2014246789A patent/JP6078049B2/ja active Active
-
2020
- 2020-01-02 US US16/732,487 patent/US11143660B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2795575A1 (en) | 2011-11-17 |
| WO2011143048A2 (en) | 2011-11-17 |
| EP2569639A2 (en) | 2013-03-20 |
| RU2564089C2 (ru) | 2015-09-27 |
| ES2534246T3 (es) | 2015-04-21 |
| WO2011143048A3 (en) | 2012-01-05 |
| AU2011253230B2 (en) | 2014-07-17 |
| CN102884434A (zh) | 2013-01-16 |
| DK2569639T3 (en) | 2015-04-20 |
| ZA201208037B (en) | 2016-10-26 |
| US10564169B2 (en) | 2020-02-18 |
| US11143660B2 (en) | 2021-10-12 |
| EP2569639B1 (en) | 2015-02-11 |
| US20130041024A1 (en) | 2013-02-14 |
| CN102884434B (zh) | 2015-08-19 |
| JP2013532127A (ja) | 2013-08-15 |
| JP6078049B2 (ja) | 2017-02-08 |
| JP6099560B2 (ja) | 2017-03-22 |
| JP2015096071A (ja) | 2015-05-21 |
| US20200132699A1 (en) | 2020-04-30 |
| BR112012025841A2 (pt) | 2016-06-28 |
| CA2795575C (en) | 2017-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012153681A (ru) | Способы диагностики, контроля и профилактики воспаления и смягчения воспалительных состояний у псовых | |
| Pan et al. | Inflammation and sarcopenia: a focus on circulating inflammatory cytokines | |
| Valdes et al. | Osteoarthritis and ageing | |
| Harasymowicz et al. | Regional differences between perisynovial and infrapatellar adipose tissue depots and their response to class II and class III obesity in patients with osteoarthritis | |
| Castillero et al. | Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy | |
| Welch | Nutritional influences on age-related skeletal muscle loss | |
| Höper et al. | Wax esters from the marine copepod Calanus finmarchicus reduce diet-induced obesity and obesity-related metabolic disorders in mice | |
| Damani et al. | The role of prunes in modulating inflammatory pathways to improve bone health in postmenopausal women | |
| Tang et al. | Evaluating the activity of sodium butyrate to prevent osteoporosis in rats by promoting osteal GSK-3β/Nrf2 signaling and mitochondrial function | |
| Liisberg et al. | Intake of a Western diet containing cod instead of pork alters fatty acid composition in tissue phospholipids and attenuates obesity and hepatic lipid accumulation in mice | |
| Okman-Kilic | Estrogen deficiency and osteoporosis | |
| BR112015019278A2 (pt) | processo de elastografia multi-impulsional | |
| El Kebbaj et al. | Argan oil prevents down-regulation induced by endotoxin on liver fatty acid oxidation and gluconeogenesis and on peroxisome proliferator-activated receptor gamma coactivator-1α,(PGC-1α), peroxisome proliferator-activated receptor α (PPARα) and estrogen related receptor α (ERRα) | |
| AU2011253230A1 (en) | Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines | |
| Abraham et al. | The role of loading in murine models of rotator cuff disease | |
| Lisco et al. | Endocrine, Metabolic, and Immune Pathogenesis of Postmenopausal Osteoporosis. Is there a Therapeutic Role in Natural Products? | |
| Aoi et al. | Skeletal muscle: novel and intriguing characteristics as a secretory organ | |
| Hyder | PGlyRP3 concerts with PPARγ to attenuate DSS-induced colitis in mice | |
| Choi et al. | Anti-osteoarthritis effects of Pomegranate, Eucommiae cortex and Achyranthis radix extracts on the primary cultured rat articular chondrocytes | |
| Vulcan | Role of β-Hydroxy-β-methylbutyrate (HMB) on inflammation after eccentric exercise | |
| KOMIYA | Study on regulation of skeletal muscle characteristics by food components. | |
| Shao et al. | Dietary supplementation with grape seed extract improves energy metabolism by enhancing the production of inosine in the rumen of dairy cows | |
| Zhu et al. | Fine Particulate Matter Exposure Induces Toxicity by Regulating Nuclear Factor-κB/toll-like Receptor 4/myeloid Differentiation Primary Response Signaling Pathways in RAW264. 7 Cells | |
| Dar et al. | Therapeutic potential of d‐limonene in rheumatoid arthritis: Modulation of inflammatory, anti‐inflammatory cytokines, and prostaglandin E2 | |
| Dulyapraphant | The efficiency of pcso-524 on feline osteoarthritis associated with chronic kidney disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180506 |